1. Home /
    2. Altai Protocol Library /
  2. New Indication: Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer

New Indication: Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer
Study:
  • Multicenter, international, phase 2 study
  • Metastatic HER2-mutant NSCLC, refractory to standard treatment
  • Trastuzumab deruxtecan (N=91)
Efficacy:
  • mPFS: 8.2 mos, mOS:17.8 mos
  • mDOR: 9.3 mos
Safety:
  • All patients had adverse events
  • Grade 3 AE >= 46%
  • Grade 3 >= neutropenia: 19%, anemia:10%
  • Grade 5 AE: 13 patients, serious AE:20%, pneumonitis:13%, ILD:5%

N Engl J Med. 2022 Jan 20;386(3):241-251.

Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer

https://doi.org/10.1056/nejmoa2112431

Reviewed by Hasan Cagri Yildirim, MD on Mar 28, 2022

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More